Ameriprise’s XTL Biopharmaceuticals XTLB Stock Holding History

Ameriprise’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-22	Closed	-$1K	–	4455
2014 Q3	$1K	Hold	22	–	–	﹤0.01%	5591
2014 Q2	$1K	Hold	22	–	–	﹤0.01%	5386
2014 Q1	$2K	Hold	22	–	–	﹤0.01%	5074
2013 Q4	$1K	Hold	22	–	–	﹤0.01%	5017
2013 Q3	$2K	Buy	+22	New	+$2.71K	﹤0.01%	5416

Other funds holding XTLB

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ameriprise's XTLB Position: Q4 2014 in Review

Ameriprise sold out of XTL Biopharmaceuticals (XTLB) in Q4 2014, closing a stake of 22 shares — an estimated $1K sold.

Ameriprise first reported a position in XTLB in Q3 2013 and held it in 5 quarters. The position peaked at $2K in Q1 2014. 3 funds tracked by Wall St. Rank hold XTLB as of Q4 2014.

Ameriprise reported no remaining XTL Biopharmaceuticals position as of Q4 2014 after selling out during the quarter.
Ameriprise sold 22 XTL Biopharmaceuticals shares in Q4 2014, an estimated $1K.
Ameriprise first reported a position in XTL Biopharmaceuticals in Q3 2013 and held it in 5 quarters.
Ameriprise's XTL Biopharmaceuticals position peaked at $2K in Q1 2014.
3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q4 2014.

Based on Ameriprise's 13F filing for Q4 2014, filed 13 Feb 2015.